Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors

• Status: Unknown status
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Knowing the impact that the use of ESL as adjunctive treatment of partial epilepsy has on cardiovascular risk factors measured by biochemical and ultrasound parameters compared with enzyme-inducing AEDs.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
• Treatments: Eslicarbazepine acetate

Criteria

Inclusion Criteria:

• Patients over 18 years

• patients definitively diagnosed Focal Epilepsy based on clinical criteria and additional tests.

• patients with stable and identifiable antiepileptic treatment during the last two years.

• patients according to the investigator are able to provide clinical data necessary for the development of the study

• Patients who signed informed consent

Exclusion Criteria:

• Patients who, according to their evolution and demands of clinical practice, their previous treatment has to be changed for this reason breach inclusion criteria and / or attachment to one of the study groups.